Several SOCs demonstrated positive signals in glioblastoma patients treated with bevacizumab, including “Musculoskeletal and connective tissue disorders” (ROR = 2.77, 95% CI: 2.46–3.12), “Vascular disorders” (ROR = 2.17, 95% CI: 1.98–2.39), “Renal and urinary disorders” (ROR = 1.63, 95% CI: 1.43–1.87), “Nervous system disorders” (ROR = 1.46, 95% CI: 1.38–1.53), and “Investigations” (ROR = 1.36, 95% CI: 1.29–1.43). The gene discussed is CISH; the disease is glioblastoma.